Core Viewpoint - Bibet has successfully listed on the STAR Market, marking its entry as one of the first newly registered companies in the growth tier of the STAR Market, with a significant opening increase of 175.03% on its first trading day [1] Company Overview - Bibet is a biopharmaceutical company focused on innovative drug development, guided by clinical value, and specializes in major disease areas such as tumors, autoimmune diseases, and metabolic diseases [1] - The company relies on its self-developed core technology platform to continuously develop first-in-class drugs and innovative drugs that meet unmet clinical needs [1] Product Pipeline - Bibet has one approved breakthrough therapy drug, BEBT-908 (injectable hydrochloride ipilimumab), for the treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) [1] - The company has BEBT-209 in Phase III clinical trials and BEBT-109 has been approved to start Phase III clinical trials, with five products currently in Phase I clinical trials [1] - Additionally, multiple innovative drug products are in preclinical research stages [1]
必贝特上市首日高开175.03%